

• **Supporting Information**

One-pot synthesis of 2,3-disubstituted dihydrobenzofurans and
benzofurans *via* rhodium-catalyzed intramolecular C-H insertion
reaction

Xueji Ma^a, Feifei Wu^a, Xiaofei Yi^a, Hangxiang Wang^{b,c*}, and Wanzhi Chen^{a*}

^a Department of Chemistry, Zhejiang University, Hangzhou 310028, China.

^b First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou,
310003, China.

^c Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases,
Zhejiang University, Hangzhou, 310003, China.

Email: chenwzz@zju.edu.cn and wanghx@zju.edu.cn

I.	General Information.....	2
II.	Experimental Section.....	2
	1. Synthesis of starting materials 1	2
	2. Optimization of Reaction Conditions.....	10
	3. General procedure for the synthesis of 2	11
	4. General procedure for the synthesis of 3	15
	5. General procedure for the synthesis of 4	17
	6. Synthesis of 5 and 6	24
III.	Reference.....	25
IV.	NMR Spectra.....	27

I. General Information.


¹H NMR spectra were recorded in deuterated solvents on a Bruker 400 (400 MHz) spectrometer and calibrated to the residual solvent peak or tetramethylsilane (δ = 0 ppm). Multiplicities are abbreviated as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublet, dt = doublet of triplet, br = broad. J-values are in Hz. HRMS was measured by a Finnigan MA+ mass spectrometer or a GCT Premier (7000FWHM). Organic solvents used were dried by standard methods when necessary. Commercially obtained reagents were used without further purification. All reactions were monitored by TLC with Huanghai GF₂₅₄ silica gel coated plates. Flash column chromatography was carried out using 300-400 mesh silica gel at increased pressure. All reactions were performed under argon using standard Schlenk techniques.

II. Experimental Section

1. Synthesis of starting materials 1


N-Sulfonyl-1,2,3-triazoles **1** were prepared from the corresponding alkynes and sulfonyl azides according to previously reported synthetic procedures.¹

Following the reported procedure, copper(I) thiophene-2-carboxylate (0.1 mmol), sulfonyl azide (2 mmol), alkyne (2.6 mmol) in wet CHCl₃ (7 mL) was stirred at room temperature until the total consumption of sulfonyl azide. The mixture was then diluted with 15 mL of saturated NH₄Cl and extracted with EtOAc (3 x 15 mL). The combined organic layers were dried over MgSO₄ and concentrated under reduced pressure. The mixture obtained was then filtrated over a pad of silica gel (3 x 10 cm) with a mixture of *n*-hexane/EtOAc (1:1) to afford the desired product.




4-(2-(Benzyloxy)phenyl)-1-tosyl-1*H*-1,2,3-triazole (1a)

White solid; m.p.: 126-127 °C; ^1H NMR (400 MHz, CDCl_3): δ = 8.48 (s, 1H), 8.32 (dd, J = 7.6, 1.6 Hz, 2H), 7.88 (d, J = 8.4 Hz, 2H), 7.44-7.48 (m, 5H), 7.32-7.34 (m, 3H), 7.03-7.08 (m, 2H), 5.20 (s, 2H), 2.43 (s, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ = 155.1, 146.9, 142.9, 138.4, 133.4, 130.3, 129.9, 128.9, 128.5, 128.4, 127.7, 122.4, 121.3, 118.1, 112.1, 70.7, 21.8; HRMS (ESI, m/z): calcd. for $\text{C}_{22}\text{H}_{20}\text{N}_3\text{O}_3\text{S}$ ($\text{M}+\text{H}$) $^+$: 406.1225, found: 406.1129.



4-(2-((4-Methylbenzyl)oxy)phenyl)-1-tosyl-1*H*-1,2,3-triazole (1b)


White solid; m.p.: 135-136 °C; ^1H NMR (400 MHz, CDCl_3): δ = 8.49 (s, 1H), 8.31 (dd, J = 7.6, 1.6 Hz, 1H), 7.88 (d, J = 8.4 Hz, 2H), 7.29-7.34 (m, 5H), 7.25 (d, J = 8.4 Hz, 2H), 7.02-7.08 (m, 2H), 5.16 (s, 2H), 2.42 (s, 3H), 2.41 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ = 155.2, 146.9, 142.9, 138.2, 133.5, 133.4, 130.3, 129.8, 129.5, 128.5, 128.1, 127.7, 122.4, 121.3, 118.1, 112.2, 70.6, 21.8, 21.3; HRMS (ESI, m/z): calcd. for $\text{C}_{23}\text{H}_{22}\text{N}_3\text{O}_3\text{S}$ ($\text{M}+\text{H}$) $^+$: 420.1382, found: 420.1375.



4-(2-((3-Methylbenzyl)oxy)phenyl)-1-tosyl-1*H*-1,2,3-triazole (1c)


White solid; m.p.: 117-118 °C; ^1H NMR (400 MHz, CDCl_3): δ = 8.52 (s, 1H), 8.32 (d, J = 7.6 Hz, 1H), 7.88 (d, J = 7.6 Hz, 2H), 7.30-7.35 (m, 5H), 7.22-7.25 (m, 2H), 7.02-7.05 (m, 2H), 5.16 (s, 2H), 2.44 (s, 3H), 2.42 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ

= 155.2, 146.9, 142.8, 138.7, 136.3, 133.5, 130.3, 129.8, 129.1, 128.7, 128.5, 128.3, 128.0, 124.7, 122.5, 121.3, 118.1, 112.1, 70.8, 21.8, 21.5; HRMS (ESI, m/z): calcd. for C₂₃H₂₂N₃O₃S (M+H)⁺: 420.1382, found: 420.1377.




4-(2-((4-Chlorobenzyl)oxy)phenyl)-1-tosyl-1H-1,2,3-triazole (1d)

White solid; m.p.: 125-126 °C; ¹H NMR (400 MHz, CDCl₃): δ = 8.43 (s, 1H), 8.30 (dd, *J* = 7.6, 1.2 Hz, 1H), 7.91 (d, *J* = 8.0 Hz, 2H), 7.29-7.43 (m, 7H), 7.08 (t, *J* = 7.6 Hz, 1H), 6.98-7.00 (d, *J* = 8.4 Hz, 1H), 5.17 (s, 2H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 154.9, 147.1, 142.8, 134.9, 134.3, 133.4, 130, 3, 129.8, 129.0, 128.9, 128.5, 128.2, 122.2, 121.6, 118.2, 112.2, 68.9, 21.8; HRMS (ESI, m/z): calcd. for C₂₂H₁₉ClN₃O₃S (M+H)⁺: 440.0836, found: 440.0839.




4-(2-((3-Chlorobenzyl)oxy)phenyl)-1-tosyl-1H-1,2,3-triazole (1e)

White solid; m.p.: 147-148 °C; ¹H NMR (400 MHz, CDCl₃): δ = 8.44 (s, 1H), 8.30 (d, *J* = 7.2 Hz, 1H), 7.93 (d, *J* = 7.6 Hz, 2H), 7.30-7.35 (m, 7H), 7.09 (t, *J* = 7.2 Hz, 1H), 7.00 (d, *J* = 8.0 Hz, 1H), 5.17 (s, 2H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 154.9, 147.1, 142.7, 138.5, 134.8, 133.4, 133.3, 130.4, 130.2, 129.9, 128.6, 128.5, 128.3, 127.7, 125.7, 122.2, 121.6, 118.1, 112.1, 69.9, 21.8; HRMS (ESI, m/z): calcd. for C₂₂H₁₉ClN₃O₃S (M+H)⁺: 440.0836, found: 440.0840.




4-(2-((3-Fluorobenzyl)oxy)phenyl)-1-tosyl-1*H*-1,2,3-triazole (1f)

White solid; m.p.: 129-130 °C; ¹H NMR (400 MHz, CDCl₃): δ = 8.46 (s, 1H), 8.30 (dd, *J* = 7.6, 1.6 Hz, 1H), 7.93 (d, *J* = 8.0 Hz, 2H), 7.41-7.45 (m, 1H), 7.30-7.36 (m, 3H), 7.22-7.25 (m, 1H), 7.07-7.15 (m, 3H), 6.99 (d, *J* = 8.0 Hz, 1H), 5.19 (s, 2H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 154.8, 147.1, 142.8, 139.0, 133.4, 130.6, 130.5, 130.4, 129.9, 128.5, 128.3, 123.2, 123.1, 122.3, 121.6, 118.2, 115.5, 115.3, 114.5, 114.3, 112.0, 69.9, 69.8, 21.8; HRMS (ESI, *m/z*): calcd. for C₂₂H₁₉FN₃O₃S (M+H)⁺: 424.1131, found: 424.1136.



4-(2-((3-Methoxybenzyl)oxy)phenyl)-1-tosyl-1*H*-1,2,3-triazole (1g)


White solid; m.p.: 130-131 °C; ¹H NMR (400 MHz, CDCl₃): δ = 8.50 (s, 1H), 8.31 (d, *J* = 7.6 Hz, 1H), 7.90 (d, *J* = 8.0 Hz, 2H), 7.30-7.40 (m, 4H), 7.96-7.09 (m, 5H), 5.17 (s, 2H), 3.85 (s, 3H), 2.42 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 160.1, 155.1, 146.9, 142.9, 137.9, 133.5, 130.3, 129.9, 129.8, 128.5, 128.1, 122.4, 121.4, 119.8, 118.1, 113.9, 113.1, 112.1, 70.6, 55.3, 21.8; HRMS (ESI, *m/z*): calcd. for C₂₃H₂₂N₃O₄S (M+H)⁺: 436.1331, found: 436.1327.



4-(2-((3-Trifluorobenzyl)oxy)phenyl)-1-tosyl-1*H*-1,2,3-triazole (1h)


White solid; m.p.: 134-135 °C; ¹H NMR (400 MHz, CDCl₃): δ = 8.41 (s, 1H), 8.33 (dd, *J* = 7.6, 1.6 Hz, 1H), 7.91 (d, *J* = 8.0 Hz, 2H), 7.61-7.71 (m, 4H), 7.32-7.34 (m, 3H), 7.10 (t, *J* = 7.6 Hz, 1H), 7.01 (d, *J* = 8.0 Hz, 1H), 5.25 (s, 2H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 154.8, 147.1, 142.6, 137.4, 133.4, 130.9, 130.3, 129.9,

129.5, 128.5, 128.3, 125.4, 125.3, 124.4, 124.3, 122.1, 121.7, 118.2, 112.0, 69.9, 21.8;
HRMS (ESI, m/z): calcd. for C₂₃H₁₉F₃N₃O₃S (M+H)⁺: 474.1099, found: 474.1106.




4-(2-((4-Methoxybenzyl)oxy)phenyl)-1-tosyl-1H-1,2,3-triazole (1i)

White solid; m.p.: 146-147 °C; ¹H NMR (400 MHz, CDCl₃): δ = 8.44 (s, 1H), 8.30 (d, *J* = 7.6, 1H), 7.88 (d, *J* = 8.0 Hz, 2H), 7.37 (d, *J* = 8.4 Hz, 2H), 7.31-7.34 (m, 3H), 7.03-7.07 (m, 2H), 6.99 (d, *J* = 8.4 Hz, 2H), 5.12 (s, 2H), 3.87 (s, 3H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 159.8, 155.2, 147.0, 142.9, 133.5, 130.3, 129.8, 128.5, 128.0, 122.4, 121.2, 118.1, 114.2, 112.2, 70.5, 55.4, 21.8; HRMS (ESI, m/z): calcd. for C₂₃H₂₂N₃O₄S (M+H)⁺: 436.1331, found: 436.1329.




4-(2-((tert-Butyl)benzyl)oxy)phenyl)-1-tosyl-1H-1,2,3-triazole (1j)

White solid; m.p.: 139-141 °C; ¹H NMR (400 MHz, CDCl₃): δ = 8.47 (s, 1H), 8.30 (dd, *J* = 6.4, 1.2 Hz, 1H), 7.86 (d, *J* = 8.4 Hz, 2H), 7.49 (d, *J* = 8.4 Hz, 2H), 7.38 (d, *J* = 8.0 Hz, 2H), 7.30-7.33 (m, 3H), 7.00-7.08 (m, 1H), 5.17 (s, 2H), 2.42 (s, 3H), 1.38 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ = 155.3, 151.6, 146.9, 142.9, 133.6, 133.4, 130.3, 129.8, 128.4, 128.0, 127.6, 125.7, 122.5, 121.2, 118.1, 112.2, 70.5, 34.7, 31.4, 21.8; HRMS (ESI, m/z): calcd. for C₂₆H₂₈N₃O₃S (M+H)⁺: 462.1851, found: 462.1853.




4-(2-((2-Fluorobenzyl)oxy)phenyl)-1-tosyl-1*H*-1,2,3-triazole (1k)

White solid; m.p.: 107-108 °C; ¹H NMR (400 MHz, CDCl₃): δ = 8.47 (s, 1H), 8.30 (dd, *J* = 7.6, 1.2 Hz, 1H), 7.91 (d, *J* = 8.4 Hz, 2H), 7.40-7.45 (m, 2H), 7.32-7.34 (m, 3H), 7.18-7.25 (m, 2H), 7.05-7.09 (m, 2H), 5.27 (s, 2H), 2.42 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 154.8, 146.9, 142.8, 133.4, 130.5, 130.4, 130.3, 130.1, 130.0, 129.8, 128.5, 128.2, 124.5, 124.4, 123.4, 122.4, 121.6, 118.3, 115.8, 115.6, 112.1, 64.5, 64.5, 21.8; HRMS (ESI, *m/z*): calcd. for C₂₂H₁₉FN₃O₃S (M+H)⁺: 424.1131, found: 424.1128.


**4-(2-((2-Chlorobenzyl)oxy)phenyl)-1-tosyl-1*H*-1,2,3-triazole (1l)**

White solid; m.p.: 136-137 °C; ¹H NMR (400 MHz, CDCl₃): δ = 8.51 (s, 1H), 8.30 (d, *J* = 7.6 Hz, 1H), 7.92 (d, *J* = 8.4 Hz, 2H), 7.45-7.50 (m, 2H), 7.25-7.34 (m, 5H), 7.08 (t, *J* = 7.6 Hz, 1H), 7.01 (d, *J* = 8.4 Hz, 1H), 5.32 (s, 2H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 154.8, 147.0, 142.8, 134.0, 133.4, 133.2, 130.4, 129.9, 129.8, 129.7, 129.5, 128.5, 128.3, 127.2, 122.4, 121.6, 118.2, 112.2, 67.9, 21.8; HRMS (ESI, *m/z*): calcd. for C₂₂H₁₉ClN₃O₃S (M+H)⁺: 440.0836, found: 440.0831.

**4-(2-Ethoxyphenyl)-1-tosyl-1*H*-1,2,3-triazole (1m)**


White solid; m.p.: 136-137 °C; ¹H NMR (400 MHz, CDCl₃): δ = 8.59 (s, 1H), 8.31 (d, *J* = 7.6 Hz, 1H), 8.01 (d, *J* = 8.0 Hz, 2H), 7.37 (d, *J* = 8.0 Hz, 2H), 7.31 (t, *J* = 7.6 Hz, 1H), 7.04 7.31 (t, *J* = 7.6 Hz, 1H), 6.95 (d, *J* = 8.0 Hz, 1H), 4.18 (q, *J* = 6.8 Hz, 2H), 2.43 (s, 3H), 1.55 (t, *J* = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 155.7, 140.9, 132.5, 129.1, 129.0, 128.4, 126.0, 124.8, 124.7, 121.4, 112.1, 111.8, 64.5, 21.4, 14.7;

HRMS (ESI, m/z): calcd. for $C_{17}H_{18}N_3O_3S$ ($M+H$)⁺: 344.1069, found: 344.1068.




4-(2-Methoxyphenyl)-1-tosyl-1H-1,2,3-triazole (1n)

White solid; m.p.: 117-119 °C; ¹H NMR (400 MHz, CDCl₃): δ = 8.57 (s, 1H), 8.31 (dd, J = 7.6 Hz, 1.6 Hz, 1H), 8.02 (d, J = 8.4 Hz, 2H), 7.37 (d, J = 8.4 Hz, 2H), 7.33 (m, 1H), 7.06 (m, 1H), 6.98 (d, J = 8.0 Hz, 1H), 3.97 (s, 3H), 2.44 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 155.9, 147.1, 142.8, 133.4, 130.4, 129.9, 128.6, 127.9, 122.0, 120.9, 117.7, 110.8, 55.5, 21.8; HRMS (ESI, m/z): calcd. for $C_{16}H_{16}N_3O_3S$ ($M+H$)⁺: 330.0912, found: 330.0907.



4-(2-Isopropoxyphenyl)-1-tosyl-1H-1,2,3-triazole (1o)


White solid; m.p.: 120-121 °C; ¹H NMR (400 MHz, CDCl₃): δ = 8.59 (s, 1H), 8.29-8.31 (m, 1H), 8.01 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 8.27-8.32 (m, 1H), 7.03-7.04 (m, 1H), 6.97 (d, J = 8.0 Hz, 1H), 4.68-4.74 (m, 1H), 2.43 (s, 3H), 1.44 (d, J = 6.0 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ = 154.3, 147.0, 143.1, 133.5, 130.4, 129.7, 128.6, 128.2, 122.1, 120.7, 118.5, 112.9, 70.7, 22.3, 21.8; HRMS (ESI, m/z): calcd. for $C_{18}H_{20}N_3O_3S$ ($M+H$)⁺: 358.1225, found: 358.1230.



4-(2-(Benzyloxy)-5-methylphenyl)-1-tosyl-1H-1,2,3-triazole (1p)


White solid; m.p.: 136-138 °C; ¹H NMR (400 MHz, CDCl₃): δ = 8.48 (s, 1H), 8.12 (s, 1H), 7.88 (d, J = 7.6 Hz, 2H), 7.43-7.48 (m, 5H), 7.31 (d, J = 7.6 Hz, 2H), 7.08-7.11

(m, 1H), 6.91-6.94 (m, 1H), 5.16 (s, 2H), 2.42 (s, 3H), 2.33 (s, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ = 153.2, 146.9, 143.0, 136.6, 133.5, 130.6, 130.3, 128.8, 128.5, 127.6, 122.4, 117.7, 112.2, 70.8, 21.8, 20.5; HRMS (ESI, m/z): calcd. for $\text{C}_{23}\text{H}_{22}\text{N}_3\text{O}_3\text{S}$ ($\text{M}+\text{H}$) $^+$: 420.1382, found: 420.1378.




4-(2-(Benzyloxy)-5-ethylphenyl)-1-tosyl-1H-1,2,3-triazole (1q)

White solid; m.p.: 123-124 °C; ^1H NMR (400 MHz, CDCl_3): δ = 8.48 (s, 1H), 8.15 (s, 1H), 7.87 (d, J = 8.4 Hz, 2H), 7.41-7.45 (m, 5H), 7.33 (d, J = 8.4 Hz, 2H), 7.12-7.15 (m, 1H), 6.93-6.96 (m, 1H), 5.16 (s, 2H), 2.63 (q, J = 7.6 Hz, 2H), 2.41 (s, 3H), 1.22 (t, J = 7.6 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ = 153.3, 146.9, 143.1, 137.2, 136.6, 133.5, 130.3, 129.2, 128.8, 128.5, 128.4, 127.7, 127.4, 117.8, 112.2, 70.8, 28.1, 21.8, 15.8; HRMS (ESI, m/z): calcd. for $\text{C}_{24}\text{H}_{24}\text{N}_3\text{O}_3\text{S}$ ($\text{M}+\text{H}$) $^+$: 434.1538, found: 434.1546.



4-(2-(Benzyloxy)-5-chlorophenyl)-1-tosyl-1H-1,2,3-triazole (1r)


White solid; m.p.: 142-144 °C; ^1H NMR (400 MHz, CDCl_3): δ = 8.47 (s, 1H), 8.29 (d, J = 2.8 Hz, 1H), 7.88 (d, J = 8.4 Hz, 2H), 7.41-7.45 (m, 5H), 7.33 ((d, J = 8.0 Hz, 3H), 7.23-7.25 (m, 1H), 6.94 (d, J = 8.4 Hz, 1H), 5.18 (s, 2H), 2.43 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ = 153.6, 147.1, 141.7, 135.9, 133.3, 130.9, 129.4, 128.9, 128.6, 128.5, 127.8, 127.6, 126.6, 122.5, 119.7, 113.5, 71.1, 21.8; HRMS (ESI, m/z): calcd. for $\text{C}_{22}\text{H}_{19}\text{ClN}_3\text{O}_3\text{S}$ ($\text{M}+\text{H}$) $^+$: 440.0836, found: 440.0835.



4-(2-(Benzyloxy)-5-(*tert*-butyl)phenyl)-1-tosyl-1*H*-1,2,3-triazole (1s)


White solid; m.p.: 109-110 °C; ¹H NMR (400 MHz, CDCl₃): δ = 8.49 (s, 1H), 8.35 (d, *J* = 2.4 Hz, 1H), 7.88 (d, *J* = 8.4 Hz, 2H), 7.41-7.46 (m, 5H), 7.25-7.33 (m, 3H), 6.96 (d, *J* = 8.4 Hz, 1H), 5.18 (s, 2H), 2.42 (s, 3H), 1.33 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ = 153.1, 146.9, 144.1, 143.2, 136.6, 133.5, 130.3, 128.8, 128.4, 127.6, 126.7, 125.1, 122.4, 117.4, 111.8, 70.7, 34.3, 31.5, 21.8; HRMS (ESI, *m/z*): calcd. for C₂₆H₂₈N₃O₃S (M+H)⁺: 462.1851, found: 462.1854.

2. Optimization of Reaction Conditions




Entry	Cat. (1 mol%)	Solvent	T (°C)	Yield (%)
1	Rh ₂ (OAc) ₄	CH ₂ Cl ₂	90	30
2	Rh ₂ (Oct) ₄	CH ₂ Cl ₂	90	51
3	Rh ₂ (OPiv) ₄	CH ₂ Cl ₂	90	57
4	Rh ₂ (TFA) ₄	CH ₂ Cl ₂	90	0
5	Rh ₂ (esp) ₄	CH ₂ Cl ₂	90	83
6	Rh₂(S-PTV)₄	CH₂Cl₂	90	91
7	Rh ₂ (S-PTTL) ₄	CH ₂ Cl ₂	90	82
8	Rh ₂ (S-NTV) ₄	CH ₂ Cl ₂	90	87
9	Rh ₂ (S-NTTL) ₄	CH ₂ Cl ₂	90	85
10	Rh ₂ (S-PTV) ₄	CH ₂ Cl ₂	80	<5
11	Rh ₂ (S-PTV) ₄	CH ₂ Cl ₂	100	90
12	Rh ₂ (S-PTV) ₄	CHCl ₃	90	90
13	Rh ₂ (S-PTV) ₄	DCE	90	81
14	Rh ₂ (S-PTV) ₄	toluene	90	73

Reaction conditions: **1a** 0.5 mmol, catalyst 0.005 mmol, solvent 4 mL, 2 h, under N₂.




3. General procedure for the synthesis of **2**

To a reaction tube with screw stopper were added triazoles **1** (0.5 mmol, 1.0 equiv) and $\text{Rh}_2(\text{S-PTV})_4$ (0.005 mmol, 0.01 equiv). The tube was evacuated and backfilled with N₂ for 3 times. DCM (4.0 mL) was added to this tube via a syringe under N₂. The reaction mixture was sealed and stirred for 2-4 hours at 90 °C. The crude product was purified by silica gel chromatography (hexane: ethyl acetate) to afford the desired product **2** as a white solid.




***N*-((2-Phenylbenzofuran-3(2*H*)-ylidene)methyl)-4-methylbenzenesulfonamide (**2a**)**

White solid; m.p.: 147-149 °C ; ¹H NMR (400 MHz, CDCl₃): δ = 7.60 (d, J = 7.6 Hz, 0.56H), 7.43 (d, J = 7.6 Hz, 1.44H), 7.21-7.36 (m, 7H), 7.14 (t, J = 7.6 Hz, 1H), 6.91 (t, J = 7.6 Hz, 1H), 6.85 (d, J = 8.0 Hz, 0.28H), 6.77 (d, J = 8.0 Hz, 0.72H), 6.77 (dd, J = 9.2, 1.6 Hz, 0.72H), 6.51 (d, J = 10.4 Hz, 0.28 H), 6.05 (s, 0.28H), 5.95 (s, 0.72H), 5.91 (d, J = 10.4 Hz, 0.28H), 6.66 (d, J = 11.2 Hz, 0.28H), 2.42 (s, 2.16H), 2.40 (s, 0.84H); ¹³C NMR (100 MHz, CDCl₃): δ = 161.8, 160.8, 143.9, 136.7, 136.6, 130.2, 129.9, 129.8, 129.4, 128.9, 128.8, 127.7, 127.3, 126.7, 126.5, 124.8, 123.4, 122.4, 121.2, 119.2, 115.9, 113.2, 110.5, 110.2, 86.6, 85.1, 21.6; HRMS (GC-TOF) for C₂₂H₁₉NO₃S: calcd. 377.1086, Found 377.1085.




***N*-((5-Methyl-2-phenylbenzofuran-3(2*H*)-ylidene)methyl)-4-methylbenzenesulfonamide (2b)**

White solid; m.p.: 143-145 °C; ¹H NMR (400 MHz, CDCl₃): δ = 7.60 (d, *J* = 8.4 Hz, 1H), 7.32-7.43 (m, 3H), 7.24-7.32 (m, 5H), 7.09-7.12 (m, 1H), 7.04 (s, 0.61 H), 6.99 (d, *J* = 8.0 Hz, 0.39 H), 6.99 (d, *J* = 8.4 Hz, 0.61H), 6.65 (d, *J* = 7.6 Hz, 1H), 6.54 (d, *J* = 10.4 Hz, 0.39H), 6.02 (s, 0.39H), 5.92 (d, *J* = 2.4 Hz, 0.61H), 5.88 (d, *J* = 10.4 Hz, 0.39H), 5.65 (d, *J* = 11.2 Hz, 0.39H), 2.42 (s, 1.83H), 2.40 (s, 1.17H), 2.31 (s, 1.83H), 2.30 (s, 1.17H); ¹³C NMR (100 MHz, CDCl₃): δ = 159.9, 158.9, 144.1, 143.9, 140.2, 136.9, 130.8, 130.6, 130.1, 129.9, 129.8, 129.7, 129.5, 128.9, 128.8, 127.7, 127.3, 126.7, 126.5, 124.6, 123.7, 122.7, 119.5, 115.6, 112.9, 110.1, 109.7, 86.7, 85.2, 21.6, 20.9; HRMS (GC-TOF) for C₂₃H₂₁NO₃S: calcd. 391.1242, Found 391.1241.




***N*-((2-(2-Fluorophenyl)benzofuran-3(2*H*)-ylidene)methyl)-4-methylbenzenesulfonamide (2c)**

White solid; m.p.: 219-221 °C; ¹H NMR (400 MHz, CDCl₃): δ = 7.78 (d, *J* = 7.6 Hz, 0.36 H), 7.66 (t, *J* = 8.0 Hz, 0.36 H), 7.53 (d, *J* = 8.0 Hz, 2H), 7.47 (d, *J* = 7.6 Hz, 0.18 H), 7.30-7.32 (m, 2.36 H), 7.21 (d, *J* = 8.0 Hz, 2H), 7.13-7.18 (m, 1.54H), 7.03-7.11 (m, 2.18H), 6.90-7.00 (m, 1.54H), 6.81 (d, *J* = 8.0 Hz, 1H), 6.70-6.73 (m, 1H), 6.65 (d, *J* = 8.0 Hz, 0.18H), 6.31(d, *J* = 2.0 Hz, 1H), 5.88 (d, *J* = 10.4 Hz, 1H), 5.23 (d, *J* = 10.4 Hz, 0.18H), 2.45 (s, 0.54H), 2.41 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 161.5, 160.9, 159.0, 143.9, 136.7, 131.1, 131.0, 129.9, 129.5, 128.4, 128.3, 127.4, 126.5, 125.1, 125.0, 124.4, 124.1, 123.9, 122.4, 121.3, 119.4, 116.1, 115.9, 113.2, 110.1, 77.9, 21.6; HRMS (GC-TOF) for C₂₂H₁₈FNO₃S: calcd. 395.0991, Found 395.0989.




***N*-((2-(4-Chlorophenyl)benzofuran-3(2*H*)-ylidene)methyl)-4-methylbenzenesulfonamide (2d)**

White solid; m.p.: 197-199 °C; ^1H NMR (400 MHz, CDCl_3): δ = 7.41 (d, J = 7.6 Hz, 2H), 7.32 (d, J = 7.6 Hz, 1H), 7.23-7.25 (m, 3H), 7.11-7.16 (m, 4H), 6.92 (t, J = 7.6 Hz, 1H), 6.73-6.77 (m, 2H), 5.95 (s, 1H), 5.76 (d, J = 10.4 Hz, 1H), 2.45 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ = 160.7, 144.2, 136.5, 135.6, 135.4, 129.9, 129.6, 129.5, 129.0, 126.4, 124.6, 123.4, 121.3, 119.3, 113.4, 110.2, 84.1, 21.6; HRMS (GC-TOF) for $\text{C}_{22}\text{H}_{18}\text{ClNO}_3\text{S}$: calcd. 411.0696, Found 411.0692.



***N*-((2-(3-Chlorophenyl)benzofuran-3(2*H*)-ylidene)methyl)-4-methylbenzenesulfonamide (2e)**


White solid; m.p.: 140-142 °C ; ^1H NMR (400 MHz, CDCl_3): δ = 7.43 (d, J = 8.4 Hz, 2H), 7.28-7.32 (m, 2H), 7.22-7.27 (m, 4H), 7.13-7.26 (m, 2H), 6.76 (t, J = 8.4 Hz, 1H), 6.71-6.77 (m, 2H), 5.94 (s, 1H), 5.77-5.85 (m, 2H), 2.42 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ = 160.6, 144.2, 139.1, 139.0, 136.4, 135.5, 130.5, 130.0, 129.9, 129.6, 127.6, 126.3, 125.9, 125.8, 124.6, 124.5, 123.0, 122.9, 121.4, 119.3, 113.5, 110.2, 84.1, 21.6; HRMS (GC-TOF) for $\text{C}_{22}\text{H}_{18}\text{ClNO}_3\text{S}$: calcd. 411.0696, Found 411.0699.




***N*-((2-(3-Methylphenyl)benzofuran-3(2*H*)-ylidene)methyl)-4-methylbenzenesulfonamide (2f)**

methylbenzenesulfonamide (2f)

White solid; m.p.: 129-131 °C; ¹H NMR (400 MHz, CDCl₃): δ = 7.41 (d, *J* = 8.4 Hz, 2H), 7.30 (d, *J* = 7.6 Hz, 1H), 7.11-7.21 (m, 5H), 7.04-7.07 (m, 2H), 6.91 (d, *J* = 7.6 Hz, 1H), 6.76 (d, *J* = 8.0 Hz, 1H), 6.68 (dd, *J* = 11.2, 2.8 Hz, 1H), 5.90 (d, *J* = 2.8 Hz, 1H), 5.78 (d, *J* = 11.2 Hz, 1H), 2.40 (s, 3H), 2.23 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 160.9, 143.9, 139.5, 136.8, 136.7, 130.6, 129.8, 129.4, 129.3, 128.3, 126.5, 124.8, 124.7, 123.5, 119.2, 113.2, 110.2, 85.2, 21.6, 21.3; HRMS (GC-TOF) for C₂₃H₂₁NO₃S: calcd. 391.1242, Found 391.1245.

***N*-((2-(3-Trifluorophenyl)benzofuran-3(2*H*)-ylidene)methyl)-4-methylbenzenesulfonamide (2g)**

White solid; m.p.: 158-159 °C; ¹H NMR (400 MHz, CDCl₃): δ = 7.56 (d, *J* = 7.6 Hz, 1H), 7.49 (s, 1H), 7.41-7.45 (m, 3H), 7.32-7.37 (m, 2H), 7.14-7.20 (m, 3H), 6.92-6.96 (m, 1H), 6.73-6.78 (m, 2H), 6.04 (d, *J* = 2.4 Hz, 1H), 5.91 (d, *J* = 11.2 Hz, 1H), 2.40 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 160.6, 144.2, 138.1, 136.4, 131.8, 131.5, 131.0, 129.9, 129.7, 129.6, 126.3, 124.7, 124.5, 124.4, 122.9, 121.4, 119.3, 113.6, 110.3, 84.0, 21.5; HRMS (GC-TOF) for C₂₃H₁₈F₃NO₃S: calcd. 445.0959, Found 445.0963.


***N*-((2-Methylbenzofuran-3(2*H*)-ylidene)methyl)-4-methylbenzenesulfonamide (2h)**

White solid; m.p.: 153-155 °C; ¹H NMR (400 MHz, CDCl₃): δ = 7.78 (d, *J* = 7.6 Hz, 1H), 7.32 (d, *J* = 7.6 Hz, 1H), 7.22-7.25 (m, 1H), 7.10 (t, *J* = 7.6 Hz, 1H), 6.94-6.97 (m, 1H), 6.82 (t, *J* = 7.6 Hz, 1H), 6.74 (d, *J* = 8.0 Hz, 1H), 6.54 (d, *J* = 9.6 Hz, 1H),

5.30-5.34 (m, 1H), 2.41 (s, 3H), 1.27 (d, $J = 6.4$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 160.7, 144.3, 136.6, 130.0, 129.4, 127.0, 126.7, 124.2, 120.7, 119.6, 111.1, 110.3, 79.5, 21.6, 19.6$; HRMS (GC-TOF) for $\text{C}_{17}\text{H}_{17}\text{NO}_3\text{S}$: calcd. 315.0929, Found 315.0927.


4. General procedure for the synthesis of 3

To a reaction tube with screw stopper were added triazoles **1** (0.5 mmol, 1.0 equiv) and $\text{Rh}_2(\text{S-PTV})_4$ (0.005 mmol, 0.01 equiv). The tube was evacuated and backfilled with N_2 for 3 times. DCM (4.0 mL) was added to this tube via a syringe under N_2 . The reaction mixture was sealed and stirred for 2-4 hours at 90 °C. After cooling to 40 °C, Pd/C (5%) was added. The mixture was stirred at 45 °C under N_2 or air (1 atm) for another 2h. Silica gel was added to the reaction mixture and the solvent was removed under reduced pressure, the crude product was purified by silica gel chromatography (hexane: ethyl acetate) to afford the desired product **3** as a white solid.




4-Methyl-N-((2-(3-trifluorophenyl)benzofuran-3-yl)methylene)benzenesulfonamide (**3b**)

White solid; m.p.: 145-147 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 9.31$ (s, 1H), 8.30 (d, $J = 7.6$ Hz, 1H), 8.06 (s, 1H), 7.91-7.96 (m, 3H), 7.85 (d, $J = 7.6$ Hz, 1H), 7.74 (t, $J = 7.6$ Hz, 1H), 7.58 (d, $J = 7.6$ Hz, 1H), 7.45 (d, $J = 7.6$ Hz, 1H), 7.34-7.41 (m, 3H), 2.44 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 163.8, 162.5, 154.6, 144.5, 135.4, 132.2, 130.0, 129.8, 129.1, 128.0, 127.9, 127.8, 126.9, 125.7, 125.6, 125.2, 124.9, 123.8, 114.1, 111.4, 21.7$; HRMS (GC-TOF) for $\text{C}_{23}\text{H}_{16}\text{F}_3\text{NO}_3\text{S}$: calcd. 443.0803, Found 443.0801.




**4-Methyl-N-((5-methyl-2-phenylbenzofuran-3-yl)methylene)benzenesulfonate
(3c)**

White solid; m.p.: 190-192 °C ; ¹H NMR (400 MHz, *d*₆-DMSO): δ = 9.07 (s, 1H), 7.87-7.91 (m, 5H), 7.66-7.68 (m, 4H), 7.47 (d, *J* = 8.0 Hz, 2H), 7.31 (d, *J* = 8.0 Hz, 1H), 2.44 (s, 3H), 2.41 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 163.8, 153.0, 144.2, 155.9, 134.8, 129.8, 129.4, 129.1, 128.4, 127.9, 127.7, 125.1, 123.4, 113.4, 110.7, 21.6, 21.5; HRMS (GC-TOF) for C₂₃H₁₉NO₃S: calcd. 389.1086, Found 389.1085.



**4-Methyl-N-((5-chloro-2-phenylbenzofuran-3-yl)methylene)benzenesulfonate
(3d)**


White solid; m.p.: 246-148 °C ; ¹H NMR (400 MHz, CDCl₃): δ = 9.31 (s, 1H), 8.26 (s, 1H), 7.92 (d, *J* = 8.0 Hz, 2H), 7.77 (d, *J* = 5.6 Hz, 2H), 7.59-7.61 (m, 3H), 7.47 (d, *J* = 8.8 Hz, 1H), 7.35-7.37 (m, 3H), 2.44 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 167.3, 163.1, 152.8, 144.5, 135.6, 131.8, 130.7, 129.5, 129.1, 127.9, 127.8, 126.7, 126.5, 123.3, 112.3, 21.7; HRMS (GC-TOF) for C₂₂H₁₆ClNO₃S: calcd. 409.0539, Found 409.0534.



**4-Methyl-N-((2-(3-chlorophenyl)benzofuran-3-yl)methylene)benzenesulfonamide
(3e)**

White solid; m.p.: 142-144 °C ; ¹H NMR (400 MHz, CDCl₃): δ = 9.31 (s, 1H), 8.29 (d, *J* = 8.0 Hz, 1H), 7.92 (d, *J* = 8.0 Hz, 2H), 7.79 (s, 1H), 7.64 (dd, *J* = 7.2, 0.8 Hz, 1H), 7.52-7.57 (m, 3H), 7.43 (t, *J* = 8.0 Hz, 1H), 7.39-7.45 (m, 3H), 2.44 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 164.2, 162.7, 154.5, 144.5, 135.5, 135.4, 131.4, 130.7, 129.9, 128.7, 128.0, 127.3, 126.8, 125.8, 125.1, 125.0, 123.7, 113.8, 111.3, 21.7; HRMS (GC-

TOF) for C₂₂H₁₆ClNO₃S: calcd. 409.0539, Found 409.0533.




4-Methyl-N-((2-methylbenzofuran-3-yl)methylene)benzenesulfonate (3f)

White solid; m.p.: 159-161 °C; ¹H NMR (400 MHz, CDCl₃): δ = 9.22 (s, 1H), 8.12 (d, *J* = 6.8 Hz, 1H), 7.91 (d, *J* = 8.0 Hz, 2H), 7.44 (d, *J* = 8.4 Hz, 1H), 7.30-7.35 (m, 4H), 2.74 (s, 3H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 168.1, 161.8, 154.4, 144.2, 136.1, 129.7, 127.7, 125.7, 124.6, 124.5, 122.6, 113.7, 110.8, 21.6, 13.4; HRMS (GC-TOF) for C₁₇H₁₅NO₃S: calcd. 313.0773, Found 313.0775.

5. General procedure for the synthesis of 4


To a reaction tube with screw stopper were added triazoles **1** (0.5 mmol, 1.0 equiv) and Rh₂(S-PTV)₄ (0.005 mmol, 0.01 equiv). The tube was evacuated and backfilled with N₂ for 3 times. DCM (4.0 mL) was added to this tube via a syringe under N₂. The reaction mixture was sealed and stirred for 2-4 hours at 90 °C. After **1** was consumed completely and cooled to 40 °C, Pd/C (5%) added. The mixture was stirred at 45 °C under H₂ (1 atm) for another 3h. Silica gel was added to the reaction mixture and the solvent was removed under reduced pressure, the crude product was purified by silica gel chromatography (hexane: ethyl acetate) to afford the desired product **4** as a white solid.



N-((2-Phenylbenzofuran-3-yl)methyl)-4-methylbenzenesulfonamide (4a)


White solid; m.p.: 164-166 °C; ¹H NMR (400 MHz, CDCl₃): δ = 7.76 (d, *J* = 8.4 Hz, 2H), 7.60-7.63 (m, 2H), 7.39-7.47 (m, 4H), 7.26-7.34 (m, 4H), 7.20 (t, *J* = 7.2 Hz,

1H), 4.56 (br, 1H), 4.43 (d, $J = 5.6$ Hz, 2H), 2.45 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 153.9, 153.4, 143.7, 136.3, 129.7, 129.1, 128.9, 128.7, 127.3, 127.2, 124.9, 123.1, 119.4, 111.2, 110.1, 37.7, 21.6$; HRMS (GC-TOF) for $\text{C}_{22}\text{H}_{19}\text{NO}_3\text{S}$: calcd. 377.1086, Found 377.1089.




***N*-((2-(*p*-Tolyl)benzofuran-3-yl)methyl)-4-methylbenzenesulfonamide (4b)**

White solid; m.p.: 175-177 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 7.76$ (d, $J = 8.0$ Hz, 2H), 7.51 (d, $J = 8.0$ Hz, 2H), 7.45 (d, $J = 8.4$ Hz, 1H), 7.29-7.31 (m, 4H), 7.17-7.22 (m, 3H), 4.51 (br, 1H), 4.42 (d, $J = 5.6$ Hz, 2H), 2.46 (s, 3H), 2.41 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 153.8, 143.6, 139.3, 136.4, 129.7, 129.6, 129.5, 129.4, 128.8, 127.4, 127.1, 124.7, 123.0, 119.2, 111.2, 109.4, 37.7, 21.6, 21.4$; HRMS (GC-TOF) for $\text{C}_{23}\text{H}_{21}\text{NO}_3\text{S}$: calcd. 391.1242, Found 391.1244.



***N*-((2-(*m*-Tolyl)benzofuran-3-yl)methyl)-4-methylbenzenesulfonamide (4c)**


White solid; m.p.: 147-148 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 7.73$ (d, $J = 8.0$ Hz, 2H), 7.38 (d, $J = 7.6$ Hz, 1H), 7.33 (d, $J = 7.6$ Hz, 1H), 7.25-7.30 (m, 3H), 7.16-7.21 (m, 2H), 4.66 (t, $J = 5.2$ Hz, 1H), 4.41 (d, $J = 5.2$, 2H), 2.43 (s, 3H), 2.38 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 153.9, 153.6, 143.6, 138.7, 136.4, 129.9, 129.7, 129.6, 128.8, 128.7, 127.8, 127.3, 124.9, 124.3, 123.0, 119.3, 111.2, 109.9, 37.8, 21.5, 21.4$; HRMS (GC-TOF) for $\text{C}_{23}\text{H}_{21}\text{NO}_3\text{S}$: calcd. 391.1242, Found 391.1240.



***N*-((2-(4-Chlorophenyl)benzofuran-3-yl)methyl)-4-methylbenzenesulfonamide**

(4d)


White solid; m.p.: 146-147 °C; ¹H NMR (400 MHz, CDCl₃): δ = 7.75 (d, *J* = 8.0 Hz, 2H), 7.56 (d, *J* = 8.8 Hz, 2H), 7.45 (d, *J* = 8.0 Hz, 1H), 7.29-7.39 (m, 6H), 7.18-7.22 (m, 1H), 4.57 (br, 1H), 4.39 (d, *J* = 5.2 Hz, 2H), 2.47 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 153.8, 152.2, 143.8, 136.2, 135.1, 129.7, 129.1, 128.6, 128.4, 128.1, 127.3, 125.2, 123.2, 119.3, 111.2, 110.4, 37.6, 21.6; HRMS (GC-TOF) for C₂₂H₁₈ClNO₃S: calcd. 411.0696, Found 411.0700.



***N*-((2-(3-Chlorophenyl)benzofuran-3-yl)methyl)-4-methylbenzenesulfonamide**

(4e)


White solid; m.p.: 153-155 °C; ¹H NMR (400 MHz, CDCl₃): δ = 7.72-7.77 (m, 2H), 7.67 (s, 1H), 7.60-7.62 (m, 1H), 7.45-7.51 (m, 2H), 7.29-7.40 (m, 5H), 7.19-7.23 (m, 1H), 4.57 (br, 1H), 4.43 (dd, *J* = 5.2, 3.2 Hz, 2H), 2.45 (s, 3H); ¹³C NMR (400 MHz, CDCl₃): δ = 153.9, 151.7, 143.8, 143.7, 136.3, 136.2, 135.0, 131.4, 130.1, 129.8, 129.7, 129.1, 128.9, 128.7, 128.4, 127.4, 127.3, 127.2, 127.1, 125.4, 125.2, 124.9, 123.3, 123.0, 119.5, 119.3, 111.3, 111.2, 111.1, 109.9, 37.7, 37.6, 21.6; HRMS (GC-TOF) for C₂₂H₁₈ClNO₃S: calcd. 411.0696, Found 411.0696.



***N*-((2-(3-Fluorophenyl)benzofuran-3-yl)methyl)-4-methylbenzenesulfonamide (4f)**


White solid; m.p.: 171-173 °C; ¹H NMR (400 MHz, CDCl₃): δ = 7.74 (d, *J* = 8.0 Hz, 2H), 7.46 (d, *J* = 8.0 Hz, 1H), 7.26-7.41 (m, 7H), 7.21 (t, *J* = 7.6 Hz, 1H), 7.09 (t, *J* = 8.0 Hz, 1H), 4.59 (br, 1H), 4.42 (d, *J* = 5.2 Hz, 2H), 2.45 (s, 3H); ¹³C NMR (100 MHz,

CDCl₃): δ = 153.8, 151.9, 143.8, 136.2, 131.7, 130.5, 129.7, 128.5, 127.3, 125.4, 123.2, 122.8, 119.5, 116.0, 114.1, 111.1, 37.5, 21.6; HRMS (GC-TOF) for C₂₂H₁₈FNO₃S: calcd. 395.0991, Found 395.0991.




***N*-((2-(3-Trifluoromethyl)phenyl)benzofuran-3-yl)methyl)-4-methylbenzenesulfonamide (4g)**

White solid; m.p.: 169-171 °C; ¹H NMR (400 MHz, CDCl₃): δ = 7.95 (s, 1H), 7.81 (d, J = 7.6 Hz, 1H), 7.71 (d, J = 8.0 Hz, 2H), 7.64 (d, J = 7.6 Hz, 1H), 7.52 (t, J = 7.6 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.39 (d, J = 7.6 Hz, 1H), 7.32 (t, J = 7.6 Hz, 1H), 7.20-7.25 (m, 3H), 4.76 (t, J = 5.2 Hz, 1H), 4.41 (d, J = 5.2 Hz, 2H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 153.9, 151.5, 143.8, 136.1, 131.6, 131.3, 130.5, 130.2, 129.7, 129.4, 128.4, 127.2, 125.6, 125.5, 124.0, 123.9, 123.3, 119.6, 111.3, 37.6, 21.5; HRMS (GC-TOF) for C₂₃H₁₈F₃NO₃S: calcd. 445.0959, Found 445.0962.




***N*-((2-(3-Methoxyphenyl)benzofuran-3-yl)methyl)-4-methylbenzenesulfonamide (4h)**

White solid; m.p.: 135-137 °C; ¹H NMR (400 MHz, CDCl₃): δ = 7.73 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 8.4 Hz, 1H), 7.25-7.32 (m, 6H), 7.16-7.20 (m, 2H), 6.93-6.96 (m, 1H), 4.63 (t, J = 5.2 Hz, 1H), 4.42 (d, J = 5.2 Hz, 2H), 3.86 (s, 3H), 2.44 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 160.0, 153.8, 153.2, 143.7, 136.3, 130.9, 129.9, 129.7, 128.6, 127.3, 125.0, 123.1, 119.5, 119.3, 115.4, 112.2, 111.2, 110.2, 55.5, 37.7, 21.6; HRMS (GC-TOF) for C₂₃H₂₁NO₄S : calcd. 407.1191, Found 407.1194.




***N*-((2-(4-Methoxyphenyl)benzofuran-3-yl)methyl)-4-methylbenzenesulfonamide (4i)**

White solid; m.p.: 169-171 °C; ¹H NMR (400 MHz, CDCl₃): δ = 7.76 (d, *J* = 8.0 Hz, 2H), 7.56 (d, *J* = 8.0 Hz, 2H), 7.43 (d, *J* = 8.4 Hz, 1H), 7.26-7.31 (m, 4H), 7.15-7.18 (m, 1H), 6.92 (d, *J* = 8.4 Hz, 2H), 4.54 (br, 1H), 4.39 (d, *J* = 5.2 Hz, 2H), 3.86 (s, 3H), 2.46 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 160.3, 153.7, 153.6, 143.7, 136.3, 129.7, 128.8, 128.6, 127.4, 124.5, 122.9, 122.3, 118.9, 114.4, 111.1, 108.5, 55.4, 37.8, 21.6; HRMS (GC-TOF) for C₂₃H₂₁NO₄S: calcd. 407.1191, Found 407.1193.



***N*-((2-(4-(*tert*-Butyl)phenyl)benzofuran-3-yl)methyl)-4-methyl Benzenesulfonamide (4j)**


White solid; m.p.: 177-179 °C; ¹H NMR (400 MHz, CDCl₃): δ = 7.77 (d, *J* = 8.4 Hz, 2H), 7.53 (d, *J* = 8.4 Hz, 2H), 7.39-7.45 (m, 3H), 7.27-7.32 (m, 4H), 7.16-7.20 (m, 1H), 4.56 (br, 1H), 4.42 (d, *J* = 5.2 Hz, 1H), 2.46 (s, 3H), 1.36 (s, 9H); ¹³C NMR (400 MHz, CDCl₃): δ = 153.8, 153.6, 152.4, 136.4, 129.7, 128.8, 127.4, 126.9, 126.8, 125.8, 124.7, 122.9, 119.2, 111.2, 109.5, 37.8, 34.8, 31.2, 21.6; HRMS (GC-TOF) for C₂₆H₂₇NO₃S: calcd. 433.1712, Found 433.1710.



***N*-((2-(2-Fluorophenyl)benzofuran-3-yl)methyl)-4-methylbenzenesulfonamide (4k)**


White solid; m.p.: 159-161 °C; ¹H NMR (400 MHz, CDCl₃): δ = 7.72 (d, *J* = 7.6 Hz, 2H), 7.56-7.60 (m, 2H), 7.46 (d, *J* = 8.0 Hz, 1H), 7.38-7.42 (m, 1H), 7.31-7.35 (m,

1H), 7.22-7.26 (m, 4H), 7.11 (t, $J = 9.2$ Hz, 1H), 4.66 (br, 1H), 4.27 (d, $J = 6.0$ Hz, 2H), 2.42 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 154.7, 147.6, 143.5, 136.5, 131.2, 131.1, 130.7, 129.6, 128.1, 127.2, 125.2, 124.7, 123.2, 120.2, 116.3, 116.1, 113.3, 111.2, 37.8, 21.5$; HRMS (GC-TOF) for $\text{C}_{22}\text{H}_{18}\text{FNO}_3\text{S}$: calcd. 395.0991, Found 395.0988.




***N*-((2-(2-Chlorophenyl)benzofuran-3-yl)methyl)-4-methylbenzenesulfonamide (4l)**

White solid; m.p.: 181-183 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 7.70$ (d, $J = 8.4$ Hz, 2H), 7.57 (d, $J = 7.6$ Hz, 1H), 7.45-7.48 (m, 2H), 7.40-7.42 (m, 2H), 7.32-7.37 (m, 2H), 7.23-7.27 (m, 3H), 4.60 (t, $J = 5.2$ Hz, 1H), 4.21 (d, $J = 5.2$ Hz, 2H), 2.42 (s, 3H); ^{13}C NMR (400 MHz, CDCl_3): $\delta = 154.6, 150.7, 143.5, 136.4, 133.9, 132.2, 130.9, 130.2, 129.7, 128.7, 127.6, 127.2, 126.9, 125.2, 123.1, 120.3, 113.3, 111.4, 38.0, 21.5$; HRMS (GC-TOF) for $\text{C}_{22}\text{H}_{18}\text{ClNO}_3\text{S}$: calcd. 411.0696, Found 411.0696.




***N*-((2-Methylbenzofuran-3-yl)methyl)methyl)-4-methylbenzenesulfonamide (4m)**

White solid; m.p.: 105-107 °C; ^1H NMR (400 MHz, CDCl_3): $\delta = 7.71$ (d, $J = 8.4$ Hz, 2H), 7.31 (d, $J = 8.0$ Hz, 1H), 7.23-7.27 (m, 3H), 7.19 (t, $J = 8.0$ Hz, 1H), 7.12-7.15 (m, 1H), 4.54 (br, 1H), 4.19 (d, $J = 5.2$ Hz, 2H), 2.41 (s, 3H), 2.31 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 153.8, 153.2, 143.5, 136.7, 129.6, 127.8, 127.1, 123.1, 122.6, 118.6, 110.7, 109.7, 37.2, 21.5, 11.9$; HRMS (GC-TOF) for $\text{C}_{17}\text{H}_{17}\text{NO}_3\text{S}$: calcd. 315.0929, Found 315.0926.




***N*-((2,2-dimethyl-2,3-dihydrobenzofuran-3-yl)methyl)-4-methylbenzenesulfonamide (4o)**

White solid; m.p.: 73-75 °C; ¹H NMR (400 MHz, CDCl₃): δ = 7.72 (d, *J* = 8.0 Hz, 1H), 7.31 (d, *J* = 8.0 Hz, 1H), 7.10-7.15 (m, 2H), 6.81 (t, *J* = 7.2 Hz, 1H), 6.72 (d, *J* = 8.0 Hz, 1H), 4.59 (br, 1H), 3.08-3.21 (m, 3H), 2.43 (s, 3H), 1.39 (s, 6H); ¹³C NMR (100 MHz, CDCl₃): δ = 158.2, 143.7, 136.4, 129.8, 129.1, 127.9, 127.1, 124.9, 120.4, 110.1, 88.2, 50.1, 43.8, 28.9, 22.0, 21.5; HRMS (GC-TOF) for C₁₈H₂₁NO₃S: calcd. 331.1242, Found 331.1239.



***N*-((5-Methyl-2-phenylbenzofuran-3-yl)methyl)-4-methylbenzenesulfonamide (4p)**


White solid; m.p.: 184-185 °C; ¹H NMR (400 MHz, CDCl₃): δ = 7.77 (d, *J* = 8.0 Hz, 2H), 7.58-7.60 (m, 2H), 7.37-7.39 (m, 3H), 7.29-7.32 (m, 3H), 7.06-7.08 (m, 1H), 6.93 (s, 1H), 4.57 (t, *J* = 4.8, 1H), 4.38 (d, *J* = 4.8, 1H), 2.46 (s, 3H), 2.36 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 153.6, 153.3, 143.7, 136.3, 132.6, 129.8, 129.7, 129.0, 128.9, 128.7, 127.4, 127.1, 126.2, 118.9, 110.7, 109.7, 37.7, 21.6, 21.3; HRMS (GC-TOF) for C₂₃H₂₁NO₃S: calcd. 391.1242, Found 391.1244.



***N*-((5-Ethyl-2-phenylbenzofuran-3-yl)methyl)-4-methylbenzenesulfonamide (4q)**


White solid; m.p.: 167-168 °C; ¹H NMR (400 MHz, CDCl₃): δ = 7.77 (d, *J* = 8.0 Hz, 2H), 7.59-7.61 (m, 2H), 7.29-7.39 (m, 6H), 7.11 (d, *J* = 8.0 Hz, 1H), 6.96 (s, 1H), 4.56 (br, 1H), 4.40 (d, *J* = 5.2 Hz, 2H), 2.65 (q, *J* = 7.6 Hz, 2H), 2.46 (s, 3H), 2.65 (t, *J* = 7.6 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 153.6, 152.4, 143.7, 139.3, 136.3,

129.8, 129.7, 129.0, 128.9, 128.7, 127.4, 127.1, 125.2, 117.7, 110.8, 109.7, 37.7, 28.8, 21.6, 16.3; HRMS (GC-TOF) for C₂₄H₂₃NO₃S: calcd. 405.1399, Found 409.1400.



***N*-((5-Chloro-2-phenylbenzofuran-3-yl)methyl)-4-methylbenzenesulfonamide (4r)**

White solid; m.p.: 168-169 °C; ¹H NMR (400 MHz, CDCl₃): δ = 7.75 (d, *J* = 8.0 Hz, 2H), 7.60-7.62 (m, 2H), 7.45 (d, *J* = 8.4 Hz, 1H), 7.39-7.41 (m, 3H), 7.27-7.32 (m, 3H), 7.19 (t, *J* = 7.6 Hz, 1H), 4.57 (br, 1H), 4.42 (d, *J* = 5.2 Hz, 2H), 2.45 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 153.8, 153.4, 143.7, 136.3, 129.7, 129.1, 128.9, 128.7, 127.3, 127.2, 124.9, 123.0, 119.4, 111.2, 110.0, 37.7, 21.6; HRMS (GC-TOF) for C₂₂H₁₈ClNO₃S: calcd. 411.0696, Found 411.0694.




***N*-((5-(*tert*-Butyl)-2-phenylbenzofuran-3-yl)methyl)-4-methylbenzenesulfonamide (4s)**

White solid; m.p.: 132-134 °C; ¹H NMR (400 MHz, CDCl₃): δ = 7.61 (d, *J* = 8.0 Hz, 2H), 7.37-7.43 (m, 6H), 7.26 (d, *J* = 8.4 Hz, 2H), 7.14 (s, 1H), 7.26 (d, *J* = 8.4 Hz, 1H), 5.86 (br, 1H), 5.00 (m, 2H), 2.65 (q, *J* = 7.6 Hz, 2H), 2.43 (s, 3H), 1.20 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ = 154.3, 146.2, 144.1, 136.3, 132.5, 130.1, 129.8, 128.9, 128.7, 128.3, 127.6, 127.4, 114.3, 114.1, 112.2, 70.9, 56.5, 34.2, 31.2, 21.8; HRMS (GC-TOF) for C₂₆H₂₇NO₃S: calcd. 433.1712, Found 433.1714.

6. Synthesis of 5 and 6


3c (195 mg, 0.5 mmol, 1.0 equiv) was dissolved in CH₃OH (10 mL), followed by addition of K₂CO₃ (276 mg, 2.0 mmol, 4.0 equiv) and H₂O (360 mg, 20.0 mmol, 40.0 equiv). The solution was stirred at room temperature until the total consumption of starting material. Crude product was collected as White solid (105 mg, 89%).



5-Methyl-2-phenylbenzofuran-3-carbaldehyde 5

White solid; m.p.: 88-89 °C; ^1H NMR (400 MHz, CDCl_3): δ = 10.33 (s, 1H), 8.08 (s, 1H), 7.83-7.86 (m, 2H), 7.55-7.58 (m, 3H), 7.43 (d, J = 8.4 Hz, 1H), 7.20 (d, J = 8.4 Hz, 1H), 2.49 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ = 186.8, 165.5, 152.5, 134.7, 131.0, 129.1, 128.8, 127.2, 125.4, 122.5, 117.4, 110.6, 21.4; HRMS (GC-TOF) for $\text{C}_{16}\text{H}_{12}\text{O}_2$: calcd. 236.0837, Found 236.0835.

4g (102 mg, 0.25 mmol, 1.0 equiv) was dissolved in CH_2Cl_2 (5 mL). Then aq HCHO (1.1equiv) and TFA (57 mg, 0.5 mmol, 2.0 equiv) were added. The solution was stirred at room temperature for overnight. Crude product was purified by chromatography to give **6** and **6'** as a white solid (92 mg, 88%).





2/4-Methoxy-6-tosyl-6,7-dihydro-5H-benzo[c]-benzofuro[2,3-e]azepine 6/6'



White solid; m.p.: 68-73 °C; ^1H NMR (400 MHz, CDCl_3): δ = 7.43-7.48 (m, 3H), 7.23-7.36 (m, 5H), 6.99 (d, J = 8.0 Hz, 1H), 6.92 (d, J = 8.0 Hz, 1H), 6.82 (d, J = 8.0 Hz, 1H), 4.91 (s, 2H), 4.73 (s, 1H), 4.56 (s, 1H), 3.89 (s, 1.36H), 3.86 (s, 1.64H), 2.29 (s, 1.36H), 2.26 (s, 1.64H); ^{13}C NMR (100 MHz, CDCl_3): δ = 159.5, 156.5, 153.7, 153.6, 149.0, 148.7, 142.9, 142.7, 136.5, 136.3, 130.9, 130.5, 130.4, 129.1, 129.0, 128.6, 128.0, 127.0, 126.8, 125.5, 125.4, 123.2, 123.0, 122.9, 118.9, 118.7, 114.7, 114.6, 114.0, 111.3, 111.2, 111.1, 111.0, 56.3, 55.5, 52.3, 46.3, 46.2, 43.7, 21.4, 21.3; HRMS (GC-TOF) for $\text{C}_{24}\text{H}_{21}\text{NO}_4\text{S}$: calcd. 419.1191, Found 419.1189.



• **III Reference:**



(1) (a) S. Chuprakov, S. W. Kwok, L. Zhang, L. Lercher and V. V. Fokin, *J. Am. Chem. Soc.*, 2009, **131**, 18034; (b) T. Miura, T. Biyajima, T. Fujii and M. Murakami, *J. Am. Chem. Soc.*, 2012, **134**, 194.



IV. NMR Spectra




























































































































































































NOE of Compounds 2e and 2h

